Globus Medical Inc Class A (GMED)

Over the past six months, Globus Medical's stock price has fluctuated, reaching $90.70 as of November 27, 2025. The price increased by 44.82% in the past month and 55.03% in the past six months. Key events impacting the stock include a Q3 CY2025 earnings beat, successful Nevro merger integration, strong musculoskeletal sales and robotics demand, product launches, and analyst ratings.

The medical devices industry, in which Globus Medical operates, generally benefits from steady demand. Specific demand seasonality for Globus Medical's products and services is not explicitly detailed in the provided search results. The industry as a whole experiences recurring revenue streams from consumables, maintenance services, and upgrades. Demand for Globus Medical's musculoskeletal solutions and enabling technologies, particularly robotics, has been surging.

Globus Medical, Inc. is a medical device company specializing in healthcare solutions for musculoskeletal disorders. They operate in the Health Technology sector, focusing on Medical Devices, Therapeutic Devices, and Surgical & Medical Instruments & Apparatus. Their products include musculoskeletal solutions like implantable devices and enabling technologies such as the ExcelsiusGPS® robotic navigation platform. The majority of the company's revenue is generated from musculoskeletal solutions, with more than half earned in the United States.

Globus Medical, Inc. operates globally with a strong presence in North America, Europe, and Asia-Pacific. More than half of its revenue is generated in the United States, but it also has a significant international presence. The company distributes its products directly and through a network of distributors in the U.S. and other countries, with operations spanning 64 countries.

Globus Medical has maintained a strong brand reputation in the past year, driven by its commitment to innovation, a comprehensive product portfolio, and successful strategic initiatives. The company is recognized as an innovation leader with a strong focus on research and development and cutting-edge technologies. The integration of NuVasive has been a significant event, creating what the company believes is the strongest sales force and best product offering in the spine industry. Consistent revenue growth and profitability contribute to a robust financial health and positive market perception. A diverse portfolio across multiple segments enhances its market presence and reputation.

Globus Medical, Inc. has a mixed ownership structure consisting of institutional, retail, and individual investors. Institutional investors hold a significant portion of the company's stock, approximately 79.01% to 95.16%. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and Janus Henderson Group Plc. Insiders own approximately 0.58% of the company's stock, while corporate insiders own 18.51% of the company.